Bull Says CSL Valued At Less Than Its Main Division -- Market Talk

Dow Jones

Jul 11

0245 GMT - CSL bull Morgans says the market is materially undervaluing the Australian biopharma company. Morgans figures that CSL shares are trading at an 18.2x enterprise multiple, well below its 10-year average of 24.7x. It adds the market appears to be valuing CSL at a 10% discount to its main Behring business, meaning investors are effectively assessing zero or negative value to CSL's flu-vaccine unit Seqirus and specialty business Vifor. Morgans points out that investor sentiment has been negatively impacted by the threat of tariffs and drug-pricing reform in the U.S. Although Morgans trims its target price and earnings estimates, it still expects CSL to rise to A$303.70/share, compared with recent trading of around A$240/share. (mike.cherney@wsj.com)

(END) Dow Jones Newswires

July 10, 2025 22:45 ET (02:45 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2550609676"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2550609676\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2550609676?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-11 10:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2550609676","market":"us","top_or_hot":-1,"title":"Bull Says CSL Valued At Less Than Its Main Division -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0245 GMT - CSL bull Morgans says the market is materially undervaluing the Australian biopharma company. Morgans figures that CSL shares are trading at an 18.2x enterprise multiple, well below its 10-year average of 24.7x. It adds the market appears to be valuing CSL at a 10% discount to its main Behring business, meaning investors are effectively assessing zero or negative value to CSL's flu-vaccine unit Seqirus and specialty business Vifor. Morgans points out that investor sentiment has been negatively impacted by the threat of tariffs and drug-pricing reform in the U.S. Although Morgans trims its target price and earnings estimates, it still expects CSL to rise to A$303.70/share, compared with recent trading of around A$240/share. (mike.cherney@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 10, 2025 22:45 ET (02:45 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Bull Says CSL Valued At Less Than Its Main Division -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBull Says CSL Valued At Less Than Its Main Division -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-07-11 10:45</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0245 GMT - CSL bull Morgans says the market is materially undervaluing the Australian biopharma company. Morgans figures that CSL shares are trading at an 18.2x enterprise multiple, well below its 10-year average of 24.7x. It adds the market appears to be valuing CSL at a 10% discount to its main Behring business, meaning investors are effectively assessing zero or negative value to CSL's flu-vaccine unit Seqirus and specialty business Vifor. Morgans points out that investor sentiment has been negatively impacted by the threat of tariffs and drug-pricing reform in the U.S. Although Morgans trims its target price and earnings estimates, it still expects CSL to rise to A$303.70/share, compared with recent trading of around A$240/share. (mike.cherney@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  July 10, 2025 22:45 ET (02:45 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7067","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2550609676","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2550609676","pubTimestamp":1752201900,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0245 GMT - CSL bull Morgans says the market is materially undervaluing the Australian biopharma company. Morgans figures that CSL shares are trading at an 18.2x enterprise multiple, well below its 10-year average of 24.7x. It adds the market appears to be valuing CSL at a 10% discount to its main Behring business, meaning investors are effectively assessing zero or negative value to CSL's flu-vaccine unit Seqirus and specialty business Vifor. Morgans points out that investor sentiment has been negatively impacted by the threat of tariffs and drug-pricing reform in the U.S. Although Morgans trims its target price and earnings estimates, it still expects CSL to rise to A$303.70/share, compared with recent trading of around A$240/share. ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7067":"生物科技","BK7508":"医药生物股","CSL.AU":"CSL LIMITED","BK7511":"ESG概念","LU1169590202.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"I\" (USD) ACC","BK7501":"新冠治疗股","SG9999004303.SGD":"Nikko AM Shenton Global Opportunities SGD","LU0728928796.USD":"abrdn SICAV I - GLOBAL SMALL&MID-CAP SDG HORIZONS EQUITY \"A\" (USD) ACC","SGXZ23171101.USD":"NIKKO AM SHENTON GLOBAL OPPORTUNITIES (USD) ACC","LU1169589451.USD":"ALLSPRING (LUX)  U.S. SELECT EQUITY \"A\" (USD) ACC","BK4086":"建筑产品","CSL":"卡莱尔伙伴"},"translate_title":"公牛称CSL的估值低于其主要部门——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CSL.AU":0.9,"CSL":1},"content_text":"0245 GMT - CSL bull Morgans says the market is materially undervaluing the Australian biopharma company. Morgans figures that CSL shares are trading at an 18.2x enterprise multiple, well below its 10-year average of 24.7x. It adds the market appears to be valuing CSL at a 10% discount to its main Behring business, meaning investors are effectively assessing zero or negative value to CSL's flu-vaccine unit Seqirus and specialty business Vifor. Morgans points out that investor sentiment has been negatively impacted by the threat of tariffs and drug-pricing reform in the U.S. Although Morgans trims its target price and earnings estimates, it still expects CSL to rise to A$303.70/share, compared with recent trading of around A$240/share. (mike.cherney@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  July 10, 2025 22:45 ET (02:45 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}